Elpida® (elsulfavirine) Weekly Oral

About Viriom

Viriom is a clinical-stage biotech company advancing a pipeline of antiviral therapies, primarily for HIV, with a mission to ensure broad global access. Its lead asset, Elpida® (elsulfavirine), is an NNRTI approved in Russia and Eurasian markets, with development ongoing for weekly oral and long-acting injectable formulations. The company is also expanding its focus to include treatments for SARS-CoV-2, influenza, Hepatitis B/C, and solid tumors, supported by a leadership team with deep virology and drug development expertise.

Therapeutic Areas